Q1 2026 Ardelyx Inc Earnings Call Transcript
Key Points
- Ardelyx Inc (ARDX) reported a 58% year-over-year revenue growth for IBSRELA, demonstrating strong commercial execution.
- The company is on track to deliver at least $1 billion in annual revenue for IBSRELA by 2029.
- XPHOZAH saw a 32% increase in total dispenses and a 19% increase in paid prescriptions year-over-year, despite a 10% decline in the overall prescription market.
- Ardelyx Inc (ARDX) has financial flexibility to invest in its pipeline, including the ACCEL Phase 3 trial for chronic idiopathic constipation (CIC).
- The company successfully refinanced its existing debt, extending the maturity and lowering the overall cost of capital.
- The company reported a net loss of $37.6 million for the first quarter of 2026, although this was an improvement from the previous year.
- R&D expenses increased to $20.2 million, primarily due to development activities for the ACCEL Phase 3 trial.
- SG&A expenses rose to $102.3 million, reflecting ongoing investments to drive commercialization demand.
- The company faces challenges with payer coverage for XPHOZAH, although it continues to ensure patient access.
- Seasonal dynamics and severe winter storms impacted IBSRELA demand in the first quarter, although growth was still achieved.
Welcome to the Ardelyx first quarter 2026 earnings call. (Operator Instructions). I would now like to turn the conference over to Lisa Caperelli, Senior Vice President of Corporate Communications and Investor Relations. Lisa, you may begin.
Thank you, Ross. Good afternoon, everyone, and welcome to our first quarter 2026 financial results and business update call. Earlier today, we issued our earnings release, which can be found on the Investor section of our website at ardelix.com.
Slides that accompany today's call can also be found on our website. On today's call, I'm joined by Mike Raab, President and CEO of Ardelyx; who will share our Q1 progress towards our 2026 priorities. Eric Foster, Chief Commercial Officer, will provide an update on the performance of IBSRELA and XPHOZAH. And Sue Hohenleitner, our Chief Financial Officer, will provide some key highlights from our financial results.
Before we begin, I'd like to remind you that some of the statements
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
